Literature DB >> 26328154

Approaching the optimal transurethral resection of a bladder tumor.

Michael Jurewicz1, Mark S Soloway1.   

Abstract

A complete transurethral resection of a bladder tumor (TURBT) is essential for adequately diagnosing, staging, and treating bladder cancer. A TURBT is deceptively difficult and is a highly underappreciated procedure. An incomplete resection is the major reason for the high incidence of recurrence following initial transurethral resection and thus to the suboptimal care of our patients. Our objective was to review the preoperative, intraoperative, and postoperative considerations for performing an optimal TURBT. The European Association of Urology, Society of International Urology, and The American Urological Association guidelines emphasize a complete resection of all visible tumor during a TURBT. This review will emphasize the various techniques and treatments, including photodynamic cystoscopy, intravesical chemotherapy, and a perioperative checklist, that can be used to help to enable a complete resection and reduce the recurrence rate. A Medline/PubMed search was completed for original and review articles related to transurethral resection and the treatment of non-muscle-invasive bladder cancer. The major findings were analyzed and are presented from large prospective, retrospective, and review studies.

Entities:  

Keywords:  Bladder cancer; checklist; fluorescence cystoscopy; narrow band imaging; transurethral resection

Year:  2014        PMID: 26328154      PMCID: PMC4548374          DOI: 10.5152/tud.2014.94715

Source DB:  PubMed          Journal:  Turk J Urol        ISSN: 2149-3235


  48 in total

1.  Optical dilator to obviate blind urethral dilatation prior to endoscopic resections.

Authors:  M S Soloway
Journal:  Urology       Date:  1988-05       Impact factor: 2.649

2.  Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study.

Authors:  Dieter Jocham; Fred Witjes; Sigrid Wagner; Bram Zeylemaker; Jeroen van Moorselaar; Marc-Oliver Grimm; Rolf Muschter; Gralf Popken; Frank König; Ruth Knüchel; Karl-Heinz Kurth
Journal:  J Urol       Date:  2005-09       Impact factor: 7.450

Review 3.  Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations.

Authors:  J Alfred Witjes; Juan Palou Redorta; Didier Jacqmin; Frank Sofras; Per-Uno Malmström; Claus Riedl; Dieter Jocham; Giario Conti; Francesco Montorsi; Harm C Arentsen; Dirk Zaak; A Hugh Mostafid; Marko Babjuk
Journal:  Eur Urol       Date:  2010-01-22       Impact factor: 20.096

4.  Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer.

Authors:  Arnulf Stenzl; Maximilian Burger; Yves Fradet; Lance A Mynderse; Mark S Soloway; J Alfred Witjes; Martin Kriegmair; Alexander Karl; Yu Shen; H Barton Grossman
Journal:  J Urol       Date:  2010-09-17       Impact factor: 7.450

5.  Does cystoscopy correlate with the histology of recurrent papillary tumours of the bladder?

Authors:  H W Herr
Journal:  BJU Int       Date:  2001-11       Impact factor: 5.588

Review 6.  Fluorescence cystoscopy in the management of bladder cancer: a help for the urologist!

Authors:  Patrice Jichlinski; Hans-Jurg Leisinger
Journal:  Urol Int       Date:  2005       Impact factor: 2.089

7.  Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy.

Authors:  Jörg Schmidbauer; Fred Witjes; Nikolaus Schmeller; Roland Donat; Martin Susani; Michael Marberger
Journal:  J Urol       Date:  2004-01       Impact factor: 7.450

8.  A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study.

Authors:  Yves Fradet; H Barton Grossman; Leonard Gomella; Seth Lerner; Michael Cookson; David Albala; Michael J Droller
Journal:  J Urol       Date:  2007-05-11       Impact factor: 7.450

9.  A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences.

Authors:  Harry W Herr; S Machele Donat
Journal:  BJU Int       Date:  2008-09-03       Impact factor: 5.588

10.  Narrow band imaging-assisted transurethral resection for non-muscle invasive bladder cancer significantly reduces residual tumour rate.

Authors:  Evelyne C C Cauberg; Charalampos Mamoulakis; Jean J M C H de la Rosette; Theo M de Reijke
Journal:  World J Urol       Date:  2011-02-25       Impact factor: 4.226

View more
  3 in total

Review 1.  Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage.

Authors:  Adithya Balasubramanian; Ashray Gunjur; Andrew Weickhardt; Nathan Papa; Damien Bolton; Nathan Lawrentschuk; Marlon Perera
Journal:  World J Urol       Date:  2022-01-27       Impact factor: 4.226

2.  Development of a Prospective Data Registry System for Non-muscle-Invasive Bladder Cancer Patients Incorporated in the Electronic Patient File System.

Authors:  Murat Akand; Tim Muilwijk; Jan Cornelissen; Siska Van Bruwaene; Kathy Vander Eeckt; Frederic Baekelandt; Pieter Mattelaer; Raf Van Reusel; Ben Van Cleynenbreugel; Steven Joniau; Frank Van Der Aa
Journal:  Front Oncol       Date:  2019-12-11       Impact factor: 6.244

Review 3.  Transurethral resection of bladder tumour (TURBT).

Authors:  Lawrence H C Kim; Manish I Patel
Journal:  Transl Androl Urol       Date:  2020-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.